We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-6.18%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$20.6B
AUM Growth
-$2.22B
Cap. Flow
+$62.6M
Cap. Flow %
0.3%
Top 10 Hldgs %
83.49%
Holding
126
New
5
Increased
17
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
TRDA icon
Entrada Therapeutics
TRDA
+$114M
2
INCY icon
Incyte
INCY
+$108M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$46.7M
4
TSVT
2seventy bio
TSVT
+$26M
5
TVTX icon
Travere Therapeutics
TVTX
+$17.7M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$66.1M
2
FLGT icon
Fulgent Genetics
FLGT
+$17.5M
3
BLUE
bluebird bio
BLUE
+$16M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$12.9M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.19%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNGX icon
76
Tango Therapeutics
TNGX
$4.21B
$8.21M 0.04%
750,000
– –
KYNB
77
Kyntra Bio
KYNB
$27.4M
$8.18M 0.04%
+23,206
New +$7.23M
EWTX icon
78
Edgewise Therapeutics
EWTX
$4.28B
$7.64M 0.04%
500,000
– –
CBAY
79
DELISTED
Cymabay Therapeutics
CBAY
$7.34M 0.04%
2,170,464
– –
MGNX icon
80
MacroGenics
MGNX
$233M
$7.1M 0.03%
442,579
– –
ITOS
81
DELISTED
iTeos Therapeutics
ITOS
$7M 0.03%
150,346
– –
NVAX icon
82
Novavax
NVAX
$1.21B
$6.89M 0.03%
48,168
-60,588
-56% -$10.4M
ALLK
83
DELISTED
Allakos
ALLK
$6.88M 0.03%
703,050
– –
TCRX icon
84
TScan Therapeutics
TCRX
$48.5M
$6.41M 0.03%
1,425,000
– –
RETA
85
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.91M 0.03%
223,976
– –
RVMD icon
86
Revolution Medicines
RVMD
$38.5B
$5.59M 0.03%
222,222
– –
HRMY icon
87
Harmony Biosciences
HRMY
$2.08B
$5.27M 0.03%
123,600
– –
NGM
88
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$5.17M 0.03%
291,801
– –
ALEC icon
89
Alector
ALEC
$169M
$4.94M 0.02%
239,228
– –
ATYR
90
aTyr Pharma
ATYR
$47.4M
$4.67M 0.02%
625,000
– –
KURA icon
91
Kura Oncology
KURA
$793M
$4.26M 0.02%
304,158
– –
DNLI icon
92
Denali Therapeutics
DNLI
$3.79B
$3.96M 0.02%
88,738
– –
BMEA icon
93
Biomea Fusion
BMEA
$88.2M
$3.91M 0.02%
524,617
– –
TCRR
94
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$3.51M 0.02%
753,064
+576,603
+327% +$3.6M
GTH
95
DELISTED
Genetron Holdings Limited ADS
GTH
$2.78M 0.01%
151,769
– –
CABA icon
96
Cabaletta Bio
CABA
$427M
$2.51M 0.01%
662,063
– –
AKRO
97
DELISTED
Akero Therapeutics
AKRO
$2.5M 0.01%
118,378
– –
VINC
98
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$2.46M 0.01%
12,069
– –
ALBO
99
DELISTED
Albireo Pharma Inc
ALBO
$2.43M 0.01%
104,521
-307,945
-75% -$8.19M
SNDX icon
100
Syndax Pharmaceuticals
SNDX
$1.7B
$2.42M 0.01%
110,729
– –
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2021 Portfolio in Review

As of Q4 2021, Baker Bros. Advisors held 126 positions worth $20.6B, down 9.7% from $22.8B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Baker Bros. Advisors's Q4 2021 filing shows 5 new, 17 increased, 8 reduced and 5 closed positions. Its largest new stake was Entrada Therapeutics: 4,704,419 shares worth $80.5M. The largest sale was Seagen Inc. Common Stock, an estimated $66.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q4 2021 buy was Entrada Therapeutics: 4,704,419 shares worth $80.5M.
  • Baker Bros. Advisors added most to Incyte in Q4 2021, an estimated $108M increase.
  • Baker Bros. Advisors's biggest Q4 2021 reduction was Seagen Inc. Common Stock, cutting an estimated $66.1M.
  • Baker Bros. Advisors fully exited Mirum Pharmaceuticals in Q4 2021, selling an estimated $12.9M.
  • Baker Bros. Advisors's ten largest holdings make up 83% of its $20.6B portfolio in Q4 2021.
  • Baker Bros. Advisors opened 5 new positions and closed 5 in Q4 2021.
  • Baker Bros. Advisors's portfolio value fell 9.7% quarter-over-quarter to $20.6B.

Based on Baker Bros. Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.